By Dean Seal Shares of Werewolf Therapeutics shot higher after the company presented Phase 1 trial data establishing proof of mechanism for its lead clinical.
MedCity News
Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials
Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines.
Shares0
Two more biotech companies are joining the public markets. Werewolf Therapeutics and Vaccitech priced their respective IPOs late Thursday, raising a combined $230 million for multiple clinical trials.
Werewolf was able to boost the size of its deal, selling 7.5 million shares, up from the 6.25 million shares that it had initially planned to offer. Those shares were priced at $16 each, right at the midpoint of the biotech’s projected price range, and the company was able to gross $120 million. Werewolf’s shares will trade on the Nasdaq under the stock symbol “HOWL.”
Werewolf Therapeutics joins pack of newly public biotechs with upsized $120M IPO bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.